Volume 4, Number 4Review ArticlesThe Picture of the Prostatic Lymphokine Network Is Becoming Increasingly ComplexBob DjavanMichael MarbergerAlessandra HandisuryaChung LeeMartin NewmanGero KramerGeorg E SteinerBPHProstatitisLeukocytePro-inflammatory cytokineInterleukinInterferon-
Volume 8, Supplement 3Review ArticlesExpanding the Role of Photoselective Vaporization of the ProstatePhotoselective Vaporization of the ProstateSteven A KaplanThe use of the potassium-titanyl-phosphate (KTP) laser for the ablative treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia (BPH) has gained wide acceptance in the urologic community. The efficacy and safety of photoselective vaporization of the prostate using 60-W or 80-W KTP have been demonstrated in multiple trials, with significant impact on special high-risk surgical populations (ie, patients with large prostates and anticoagulated patients with multiple comorbidities) with symptomatic BPH. The high-power KTP laser technique has also shown encouraging results in the management of urethral strictures. With catheter removal, improvement in voiding may not immediately occur; however, with the efficient vaporization and limited coagulation necrosis that are routinely noted with high-power KTP applications, improvement may occur in as early as a few days to 1 week. Because of the superior surgical hemostasis associated with laser prostatectomy, no restrictions on physical activity are required after the procedure, even in the immediate postoperative period. [Rev Urol. 2006;8(suppl 3):S3-S8]BPHUrethral stricturesProstatectomyKTP laserVaporization
Volume 20, Number 4Case ReviewNocturia: Finding an IdentityBenjamin M BruckerNocturia is a condition that has a tremendous impact on a patient’s health and wellbeing. Getting up 2 or more times a night to urinate fragments sleep, preventing deep, restorative stages of the sleep cycle. With safer and more effective therapies, nocturia is a treatable condition that no longer should be overlooked. The simplicity of directly targeting the cause of nocturia, the overproduction of urine (ie, nocturnal polyuria) should be considered. Noctiva™ (desmopressin acetate) nasal spray (Avadel Pharmaceuticals plc, Chesterfield, MO), a novel FDA-approved microdose desmopressin nasal spray, can reduce nighttime urine production and potentially mitigate the potential harm of nocturia. [Rev Urol. 2018;20(4):170–173 doi: 10.3909/riu0822] © 2019 MedReviews®, LLCQuality of lifeBPHLower urinary tract symptoms (LUTS)Desmopressin acetate